Anna Rose Welch articles

  1. Why Biosimilars Won’t Be “A Stake In The Heart Of Innovation”
    2/13/2018

    There has not been much discussion about how biosimilars contribute to or will impact innovation — outside of helping the healthcare system afford costly novel therapies. I found my interest in this question sparked upon reading a recent headline, "Biosimilars: The Cure for Sky-High Drug Prices Or A Stake In The Heart Of Innovation?"

  2. AmerisourceBergen: Responsible Pricing, Patient Programs Biggest Biosimilar Challenges
    2/5/2018

    In the first part of this two-part article, we touched on the two strategies for distributing biosimilars. In this article, Lozano highlights some of the common topics that pose the greatest challenges for manufacturers, in particular pricing their products and establishing patient and provider services. 

  3. 2018 CBI Biosimilars Summit Unveils New Industry Focus Areas
    1/31/2018

    As more real-world evidence demonstrating biosimilars’ efficacy and safety is released, I daresay I speak for many in the U.S. who are left asking, “What more do we need?” Well, this event turned me on to a few areas that could use some work and renewed attention.

  4. The Wholesaler’s Guide To Biosimilar Distribution
    1/29/2018

    It’s rare that I should stumble upon an article discussing how biosimilars actually end up at the hospital or pharmacy in the first place. So I took the opportunity to speak with AmerisourceBergen's Richard Lozano to get a better sense of the manufacturer-wholesaler relationship and some of the questions companies must consider as they prepare to supply their biosimilars to the market.

  5. How These Hospital Stakeholders Can Benefit Biosimilar Commercialization
    1/11/2018

    In Cinfa Biotech’s time preparing for regulatory submission and, hopefully, a future product launch, Jankowsky has noted the increasingly significant role pharmacists play in educating doctors. Much of this comes down to their holistic method of approaching biosimilars — and this was integral in establishing the company’s rationale for development.

  6. What Challenges Should Biosimilar Companies Expect In 2018?
    1/10/2018

    Whether they be IP-,real-world-data-, or ongoing market-access-related challenges, biosimilar companies should expect a busy year ahead. Biosimilar Development's editorial advisory board members share the challenges they're keeping their eyes on.

  7. 2018 Outlook: Biosimilar Trends To Watch
    1/3/2018

    Last week, I published the first installment of a three-part roundtable discussion highlighting which 2017 trends/occurrences were most notable to the members of Biosimilar Development’s editorial advisory board. In addition to discussing 2017’s impact on the future of the industry, these experts also shared their thoughts on what to expect in 2018.

  8. Top 5 Biosimilar Developments Of 2017
    12/29/2017

    These top five events reflect the steps the numerous industry stakeholders are taking to build what they hope will be a biosimilar friendly framework in the U.S. Though a number of these developments could bring positive implications for the biosimilar industry moving forward, several of these have raised a number of questions and concerns.

  9. Did The 2017 Biosimilar Industry Pave The Way For A Productive 2018?
    12/28/2017

    In the first installment of this three-part Q&A, I asked the members of the inaugural Biosimilar Development editorial advisory board to share their thoughts on significant 2017 developments and how they expect these will impact the industry in 2018.

  10. Biosimilar Evolutions To Watch For In The New Year
    12/21/2017

    Experts from Adello Biologics, PA Consulting Group, Momenta Pharmaceuticals, and Avalere Health, share which trends and challenges they’re watching closely, along with how the industry could “break from tradition” in the next few years.